We need your support to keep TheyWorkForYou running and make sure people across the UK can continue to hold their elected representatives to account.Donate to our crowdfunder
The Government has agreed the terms of our exit from the European Union, as set out in the Withdrawal Agreement. The Withdrawal Agreement offers a time-limited implementation period that provides a bridge to the future relationship, allowing business, including the life sciences industry, to continue trading as now until the end of 2020. The supply of medicines and medical supplies would remain unchanged during the implementation period.
As a responsible Government, however, we continue to prepare proportionately for all scenarios, including the unlikely outcome that we leave the EU without any deal in March 2019.
On 23 August 2018, the Department wrote to pharmaceutical companies that supply prescription-only and pharmacy medicines from, or via, the EU or European Economic Area asking them, in the event of a no-deal Brexit, to ensure they have a minimum of six weeks additional supply in the United Kingdom, over and above their business as usual operational buffer stocks, by 29 March 2019.